Unicycive Therapeutics (UNCY) Research & Development (2020 - 2026)
Unicycive Therapeutics posted quarterly Research & Development of $1.6 million for Q1 2026, down 25.98% year-on-year from $2.2 million in Q1 2025, and down 28.58% on a QoQ basis from $2.2 million in Q4 2025.
Unicycive Therapeutics (UNCY) has 7 years of Research & Development data on file, last reported at $1.6 million in Q1 2026.
- For the quarter ending Q1 2026, Research & Development fell 25.98% year-over-year to $1.6 million; the trailing twelve-month figure through Mar 2026 stood at $8.6 million (down 44.24% YoY), and the FY2025 full-year result was $9.1 million, down 54.43% from the prior year.
- Research & Development for Q1 2026 stood at $1.6 million, down from $2.2 million in the prior quarter.
- Across five years, Research & Development topped out at $12.1 million in Q4 2022 and bottomed at $82000.0 in Q2 2022.
- The 5-year median for Research & Development is $3.0 million (2023), against an average of $3.7 million.
- The widest annual swing landed in 2022, when Research & Development plunged 69.74%; it then soared 2664.63% in 2023.
- A 5-year view of Research & Development shows it stood at $12.1 million in 2022, then sank by 65.11% to $4.2 million in 2023, then grew by 24.92% to $5.3 million in 2024, then plunged by 57.45% to $2.2 million in 2025, then retreated by 28.58% to $1.6 million in 2026.
- The last three Research & Development figures came in at $1.6 million (Q1 2026), $2.2 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Unicycive Therapeutics | 181.94 Mn | 127.36 Mn | - | 1.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.61 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 2.96 Mn |
| Jun 30, 2025 | 1.75 Mn |
| Mar 31, 2025 | 2.17 Mn |
| Dec 31, 2024 | 5.29 Mn |
| Sep 30, 2024 | 3.05 Mn |
| Jun 30, 2024 | 4.87 Mn |
| Mar 31, 2024 | 6.81 Mn |
| Dec 31, 2023 | 4.23 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 2.27 Mn |
| Mar 31, 2023 | 3.03 Mn |
| Dec 31, 2022 | 12.13 Mn |
| Sep 30, 2022 | 4.80 Mn |
| Jun 30, 2022 | 82,000.00 |
| Mar 31, 2022 | 1.93 Mn |
| Dec 31, 2021 | -4.00 Mn |
| Sep 30, 2021 | 3.78 Mn |
| Jun 30, 2021 | 271,000.00 |
| Mar 31, 2021 | 184,000.00 |
| Dec 31, 2020 | -459,000.00 |
| Sep 30, 2020 | 304,000.00 |
| Jun 30, 2020 | 182,000.00 |